SequelSEC

Amphastar Pharmaceuticals, Inc. AMPH

Pharmaceutical Preparations · CIK 0001297184 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$730.02M
Fiscal year ended 2026-06-30
Operating income
$114.28M
Fiscal year ended 2026-06-30
Free cash flow
$152.89M
Fiscal year ended 2026-06-30

Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $730.02M and net income of $78.55M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Amphastar Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Amphastar Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$730.02M
Cost of revenue$381.91M
Gross profit$348.11M
Operating income$114.28M
Net income$78.55M
Research & development$94.57M
Weighted-average diluted sharesUnavailable
Pretax income$102.02M
Income tax expense$23.48M
Diluted EPSUnavailable
Selling, general & administrative$139.25M
General & administrative$92.21M
Selling & marketing$47.05M

Balance

Amphastar Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$223.61M
Total assets$1.74B
Current assets$630.95M
Total liabilities$975.61M
Current liabilities$263.20M
Total equity incl. NCI$768.16M
Temporary (mezzanine) equityUnavailable
Inventory$179.91M
Accounts receivable$144.86M
Goodwill$3.31M
Long-term debt$609.56M
Accounts payable$28.93M

Cash flow

Amphastar Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$184.61M
Capital expenditures$31.72M
Investing cash flow-$52.05M
Financing cash flow-$96.46M
Net change in cash$35.92M
Stock-based compensation$28.87M
Common dividends paidUnavailable
Common share repurchases$100.07M
Depreciation & amortizationUnavailable

Derived

Amphastar Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$152.89M
Gross margin47.7%
Operating margin15.7%
FCF margin20.9%
SBC / revenue4.0%
Current ratio2.40x
Revenue YoY growth1.0%
Net margin10.8%
R&D / revenue13.0%
CapEx / revenue4.3%
Long-term debt / equity0.79x
Effective tax rate23.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AMPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.